DUBLIN--(BUSINESS WIRE)--The "Chronic Obstructive Pulmonary Disease (COPD) - Market Insight, Epidemiology and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.
This report delivers an in-depth understanding of the Chronic Obstructive Pulmonary Disease (COPD), historical and forecasted epidemiology as well as the Chronic Obstructive Pulmonary Disease (COPD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Chronic Obstructive Pulmonary Disease (COPD) market report provides current treatment practices, emerging drugs, Chronic Obstructive Pulmonary Disease (COPD) market share of the individual therapies, current and forecasted Chronic Obstructive Pulmonary Disease (COPD) market size from 2019 to 2032 segmented by seven major markets.
The report also covers current Chronic Obstructive Pulmonary Disease (COPD) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Epidemiology
The Chronic Obstructive Pulmonary Disease (COPD) epidemiology division provide insights about historical and current Chronic Obstructive Pulmonary Disease (COPD) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted Chronic Obstructive Pulmonary Disease (COPD) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.
Country-Wise Epidemiology
The epidemiology segment also provides the Chronic Obstructive Pulmonary Disease (COPD) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Drug Chapters
Drug chapter segment of the Chronic Obstructive Pulmonary Disease (COPD) report encloses the detailed analysis of Chronic Obstructive Pulmonary Disease (COPD) marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Chronic Obstructive Pulmonary Disease (COPD) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the Chronic Obstructive Pulmonary Disease (COPD) market or expected to get launched in the market during the study period 2019-2032. The analysis covers Chronic Obstructive Pulmonary Disease (COPD) market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Market Outlook
The Chronic Obstructive Pulmonary Disease (COPD) market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Chronic Obstructive Pulmonary Disease (COPD) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a thorough detail of Chronic Obstructive Pulmonary Disease (COPD) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
Pipeline Activities
The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Chronic Obstructive Pulmonary Disease (COPD) key players involved in developing targeted therapeutics.
Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Chronic Obstructive Pulmonary Disease (COPD) emerging therapies.
Reimbursement Scenario
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
KOL Views
To keep up with current market trends, we take KOLs and SME's opinion working in Chronic Obstructive Pulmonary Disease (COPD) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Chronic Obstructive Pulmonary Disease (COPD) market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
Competitive Intelligence Analysis
The publisher performs Competitive and Market Intelligence analysis of the Chronic Obstructive Pulmonary Disease (COPD) Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.
Scope of the Report
- The report covers the descriptive overview of Chronic Obstructive Pulmonary Disease (COPD), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
- Comprehensive insight has been provided into the Chronic Obstructive Pulmonary Disease (COPD) epidemiology and treatment in the 7MM
- Additionally, an all-inclusive account of both the current and emerging therapies for Chronic Obstructive Pulmonary Disease (COPD) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
- A detailed review of Chronic Obstructive Pulmonary Disease (COPD) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Chronic Obstructive Pulmonary Disease (COPD) market
Report Highlights
- In the coming years, Chronic Obstructive Pulmonary Disease (COPD) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
- The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Obstructive Pulmonary Disease (COPD) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
- Major players are involved in developing therapies for Chronic Obstructive Pulmonary Disease (COPD). Launch of emerging therapies will significantly impact the Chronic Obstructive Pulmonary Disease (COPD) market
- A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Chronic Obstructive Pulmonary Disease (COPD)
- The in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities
Companies Mentioned
- Amgen
- AstraZeneca
- Biomarck Pharmaceuticals
- Boehringer Ingelheim Pharmaceuticals
- Chiesi Farmaceutici S.p.A.
- Circassia Pharmaceuticals Inc.
- Genentech
- GlaxoSmithKline
- Inmunotek
- Innoviva
- Mereo BioPharma
- Novartis Pharmaceuticals
- Organicell Regenerative Medicine
- Pulmotect Inc.
- Regeneron Pharmaceuticals
- Sanofi
- Sunovion Pharmaceuticals
- Tetherex Pharmaceuticals Corporation
- Theravance
- United Therapeutics
- Verona Pharma PLC
- Vertex Pharmaceuticals Incorporated
For more information about this report visit https://www.researchandmarkets.com/r/fcu1o2
